BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a ...

Incyte (NASDAQ:INCY – Free Report) had its price objective hoisted by Stifel Nicolaus from $75.00 to $77.00 in a report released on Monday morning,Benzinga reports. Stifel Nicolaus currently has a ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

Corrections and clarifications: This story has been updated to reflect that the recall was voluntarily issued by FGF Brands. The Food and Drug Administration (FDA) announced a recall for 60 baked ...

A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...